**Question:** Agent causing malignant hyperthermia -

A. Dantrolene
B. Halothane
C. Succinylcholine
D. Caffeine

**Core Concept:** Malignant hyperthermia is a rare but potentially lethal iatrogenic complication that can occur during general anesthesia. It is triggered by specific inhalational agents, sugammadex reversal agents, or muscle relaxants.

**Why the Correct Answer is Right:** Dantrolene is a ryanodine receptor antagonist, which inhibits the release of calcium from the sarcoplasmic reticulum in skeletal muscle cells. This action is essential in preventing the excessive calcium-induced hypermetabolic state and muscle rigidity characteristic of malignant hyperthermia.

**Why Each Wrong Option is Incorrect:**

A. Halothane: This volatile anesthetic is a known trigger factor for malignant hyperthermia. However, dantrolene is effective in treating the condition rather than preventing it.

B. Succinylcholine: Succinylcholine is a short-acting muscle relaxant that is not directly involved in causing malignant hyperthermia. However, it is a trigger agent for the condition.

C. Caffeine: Caffeine is a stimulant and is unrelated to malignant hyperthermia, as it does not cause or trigger the condition.

**Why Dantrolene is Right:**

Malignant hyperthermia is a pharmacogenetic disorder that can be triggered by specific anesthetic agents, particularly halothane and succinylcholine. Dantrolene is the drug of choice for treating malignant hyperthermia once it has been triggered. By inhibiting the release of calcium from the sarcoplasmic reticulum, dantrolene prevents the hypermetabolic state and hyperkalemia associated with the condition.

**Clinical Pearl:** Malignant hyperthermia is a rare but potentially fatal complication of general anesthesia. It is essential for anesthesiologists and surgeons to be aware of trigger factors and treatment options, including dantrolene, to promptly manage and prevent the severe complications associated with this condition.